Skip to content

Japt.gr

Hellenic Atherosclerosis Society
  • HOME
  • ABOUT
    • SCOPE
    • EDITORIAL BOARD
  • CURRENT ISSUE
  • ARCHIVES
    • VOLUME 15 (2024)
      • Volume 15 – Issue 1
      • Volume 15 – Issue 2
      • Volume 15 – Suppl. 1
    • VOLUME 14 (2023)
      • Volume 14 – Issue 3
      • Volume 14 – Issue 2
      • Volume 14 – Issue 1
      • Volume 14 – Suppl. 1
    • VOLUME 13 (2022)
      • Volume 13 – Issue 3
      • Volume 13 – Issue 2
      • Volume 13 – Issue 1
      • Volume 13 – Suppl. 1
    • VOLUME 12 (2021)
      • Volume 12 – Issue 1
      • Volume 12 – Issue 2
      • Volume 12 – Issue 3
      • Volume 12 – Suppl. 1
    • VOLUME 11 (2020)
      • Volume 11 – Issue 1
      • Volume 11 – Issue 2
      • Volume 11 – Issue 3
      • Volume 11 – Suppl. 1
    • VOLUME 10 (2019)
      • Volume 10 – Issue 1
      • Volume 10 – Suppl. 1
    • VOLUME 9 (2018)
      • Volume 9 – Issue 1
      • Volume 9 – Issue 2
      • Volume 9 – Issue 3
      • Volume 9 – Issue 4
    • VOLUME 8 (2017)
      • Volume 8 – Issue 1
      • Volume 8 – Issue 2
      • Volume 8 – Issue 3
      • Volume 8 – Issue 4
    • VOLUME 7 (2016)
      • Volume 7 – Issue 1
      • Volume 7 – Issue 2
      • Volume 7 – Issue 3
      • Volume 7 – Issue 4
    • VOLUME 6 (2015)
      • Volume 6 – Issue 1
      • Volume 6 – Issue 2
      • Volume 6 – Issue 3
      • Volume 6 – Issue 4
    • VOLUME 5 (2014)
      • Volume 5 – Issue 1
      • Volume 5 – Issue 2
      • Volume 5 – Issue 3
    • VOLUME 4 (2013)
      • Volume 4 – Issue 1
      • Volume 4 – Issue 2
      • Volume 4 – Issue 3
    • VOLUME 3 (2012)
      • Volume 3 – Issue 3
  • FOR AUTHORS
  • SUBMIT MANUSCRIPT
  • CONTACT
  • Menu

Category Archives: Volume 6 – Issue 2

Comparative effectiveness of acenocoumarol and low-dose dabigatran in patients with atrial fibrillation and recent ischemic stroke in everyday clinical practice

Konstantinos Tziomalos, Vasilios Giampatzis, Stella D. Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Stella-Maria Angelopoulou, Filitsa Konstantara, Christos Savopoulos, Apostolos I. Hatzitolios

Clopidogrel binds to lp-pla2 and inhibits the enzyme activity. A new pleiotropic effect of this antiplatelet drug?

M.E. Tsoumani, C.C. Tellis, M.V. Chatziathanasiadou, A.N. Katsikoudi, V.G. Kontogianni, A.G. Tzakos, A.D. Tselepis

The role of PCSK9 protein in lipoprotein (a) metabolism

E. Klouras, M. Elisaf

The composite role of PCSK9 protein

E. Klouras, M. Elisaf

SGLT2 inhibitors: what to expect in the future

Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf

The use of dapagliflozin in the treatment of type 2 diabetes mellitus

Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf

Non-alcoholic fatty liver disease in HIV-infected patients without viral hepatitis. What can we do about their cardiovascular risk?

Georgios Sfikas, Chrysoula Boutari, Konstandinos Tassios, Konstantinos Kaitanidis, Eydoxia Mitsiou, Vasilios G. Athyros

Metabolic syndrome, Barrett’s oesophagus, the risk of oesophageal adenocarcinoma, and statin treatment

Chrysoula Boutari, Stella-Maria Angelopoulou, Georgios Sfikas, Konstantinos Kaitanidis, Konstantinos Tziomalos, Vasilios G. Athyros

Intensive glucose control in patients with type 2 diabetes mellitus and incidence of cardiovascular events. Has this issue been resolved?

K. Kaitanidis, C. Boutari, A. Lazaridis, M. Doumas, K. Tziomalos, V.G. Athyros

CURRENT ISSUE

Abdominal Aortic KLF4 Expression in Hyperlipidemic Rabbits: Impact of Colchicine Regimens
Non-alcoholic fatty liver disease and cardiovascular disease; from epidemiology to clinical and nutrition management: A narrative review

Keywords

acute coronary syndrome (4) Arterial hypertension (4) arterial stiffness (5) Atherosclerosis (20) blood pressure (5) cardiovascular disease (28) cardiovascular diseases (6) Cardiovascular risk (6) childhood obesity (3) coronary artery disease (4) coronary heart disease (4) COVID-19 (4) diabetes (5) diabetes mellitus (9) diet (6) dyslipidemia (14) epidemiology (4) ezetimibe (5) Familial hypercholesterolemia (5) glucose (3) Heart failure (5) hypertension (9) inflammation (10) Ischemic stroke (3) lipoproteins (4) low-density lipoprotein cholesterol (3) Mediterranean diet (8) metabolic syndrome (7) morbidity (3) mortality (8) non-alcoholic fatty-liver disease (5) nonalcoholic fatty liver disease (3) obesity (9) omega-3 fatty acids (3) outcome (3) PCSK9 (3) PCSK9 inhibitors (5) physical activity (4) platelets (8) risk factors (3) smoking (3) statins (15) thrombosis (4) treatment (6) type 2 diabetes mellitus (4)
Journal of Atherosclerosis Prevention and Treatment    ©2025
A SiteOrigin Theme